Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

NCT03326336 is registered in ClinicalTrials.gov with GenSight Biologics as lead sponsor.

NCT NCT03326336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03326336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa
Lead sponsor
GenSight Biologics
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
September 26, 2018
Completion date
October 26, 2027
Enrollment
10 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

non-syndromic retinitis pigmentosa